Fragile X Syndrome - Pipeline Review, H2 2017

Date: September 19, 2017
Pages: 121
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: FC04677E930EN
Leaflet:

Download PDF Leaflet

Fragile X Syndrome - Pipeline Review, H2 2017
Fragile X Syndrome - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fragile X Syndrome - Pipeline Review, H2 2017, provides an overview of the Fragile X Syndrome (Genetic Disorders) pipeline landscape.

Fragile X syndrome is a genetic condition that causes a range of developmental problems including learning disabilities and cognitive impairment. Fragile X syndrome is caused by a change in a gene called FMR1. Fragile X syndrome occurs both in male and female. Symptoms include delay in crawling, walking, or twisting, hyperactive or impulsive behavior, speech and language delay and intellectual disability.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fragile X Syndrome - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Fragile X Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fragile X Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fragile X Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 4, 14 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Fragile X Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Fragile X Syndrome (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Fragile X Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Fragile X Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Fragile X Syndrome (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Fragile X Syndrome (Genetic Disorders)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Fragile X Syndrome (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Fragile X Syndrome (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Fragile X Syndrome - Overview
Fragile X Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Fragile X Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Fragile X Syndrome - Companies Involved in Therapeutics Development
Aelis Farma SAS
AMO Pharma Ltd
Anavex Life Sciences Corp
Confluence Pharmaceuticals LLC
DRI Biosciences Corp
Eli Lilly and Company
Fulcrum Therapeutics Inc
GlaxoSmithKline Plc
GW Pharmaceuticals Plc
Marinus Pharmaceuticals Inc
Neuren Pharmaceuticals Ltd
Neuron Biopharma SA
Ovid Therapeutics Inc
Sage Therapeutics Inc
Sentinel Oncology Ltd
Zynerba Pharmaceuticals Inc
Fragile X Syndrome - Drug Profiles
acamprosate calcium - Drug Profile
ACT-01 - Drug Profile
AMO-01 - Drug Profile
ANAVEX-273 - Drug Profile
AUT-00206 - Drug Profile
Bryostatin-1 - Drug Profile
cannabidiol - Drug Profile
cercosporamide - Drug Profile
Drug to Antagonize mGluR5 for Fragile X Syndrome and 16p11.2 Microdeletion Syndrome - Drug Profile
flindokalner - Drug Profile
gaboxadol - Drug Profile
ganaxolone - Drug Profile
GWP-42006 - Drug Profile
JRP-655 - Drug Profile
NNZ-2591 - Drug Profile
NST-0076 - Drug Profile
SAGE-217 - Drug Profile
SERx-519 - Drug Profile
SGE-872 - Drug Profile
Small Molecule for Fragile X-Associated Tremor Ataxia Syndrome - Drug Profile
Small Molecule to Activate FMRP for Fragile X Syndrome - Drug Profile
Small Molecule to Antagonize CB1R for Fragile X Syndrome and Down Syndrome - Drug Profile
Small Molecule to Block Kv3.1 for Fragile X Syndrome - Drug Profile
Small Molecules to Activate Slack Channels for Fragile X Syndrome - Drug Profile
Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - Drug Profile
SOL-101 - Drug Profile
TC-2153 - Drug Profile
trofinetide - Drug Profile
Fragile X Syndrome - Dormant Projects
Fragile X Syndrome - Discontinued Products
Fragile X Syndrome - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Fragile X Syndrome, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Fragile X Syndrome - Pipeline by Aelis Farma SAS, H2 2017
Fragile X Syndrome - Pipeline by AMO Pharma Ltd, H2 2017
Fragile X Syndrome - Pipeline by Anavex Life Sciences Corp, H2 2017
Fragile X Syndrome - Pipeline by Confluence Pharmaceuticals LLC, H2 2017
Fragile X Syndrome - Pipeline by DRI Biosciences Corp, H2 2017
Fragile X Syndrome - Pipeline by Eli Lilly and Company, H2 2017
Fragile X Syndrome - Pipeline by Fulcrum Therapeutics Inc, H2 2017
Fragile X Syndrome - Pipeline by GlaxoSmithKline Plc, H2 2017
Fragile X Syndrome - Pipeline by GW Pharmaceuticals Plc, H2 2017
Fragile X Syndrome - Pipeline by Marinus Pharmaceuticals Inc, H2 2017
Fragile X Syndrome - Pipeline by Neuren Pharmaceuticals Ltd, H2 2017
Fragile X Syndrome - Pipeline by Neuron Biopharma SA, H2 2017
Fragile X Syndrome - Pipeline by Ovid Therapeutics Inc, H2 2017
Fragile X Syndrome - Pipeline by Sage Therapeutics Inc, H2 2017
Fragile X Syndrome - Pipeline by Sentinel Oncology Ltd, H2 2017
Fragile X Syndrome - Pipeline by Zynerba Pharmaceuticals Inc, H2 2017
Fragile X Syndrome - Dormant Projects, H2 2017
Fragile X Syndrome - Dormant Projects, H2 2017 (Contd.1), H2 2017
Fragile X Syndrome - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Fragile X Syndrome, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

Aelis Farma SAS
AMO Pharma Ltd
Anavex Life Sciences Corp
Confluence Pharmaceuticals LLC
DRI Biosciences Corp
Eli Lilly and Company
Fulcrum Therapeutics Inc
GlaxoSmithKline Plc
GW Pharmaceuticals Plc
Marinus Pharmaceuticals Inc
Neuren Pharmaceuticals Ltd
Neuron Biopharma SA
Ovid Therapeutics Inc
Sage Therapeutics Inc
Sentinel Oncology Ltd
Zynerba Pharmaceuticals Inc
Skip to top


Acute Coronary Syndrome - Pipeline Review, H2 2016 US$ 2,000.00 Nov, 2016 · 109 pages

Ask Your Question

Fragile X Syndrome - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: